Abstract:
The significance of USP11 as a critical regulator in cancer has garnered substantial attention, primarily due to its catalytic activity as a deubiquitinating enzyme. Nonetheless, a thorough evaluation of USP11 across various cancer types in pan-cancer studies remains absent. Our analysis integrates data from a variety of sources, including five immunotherapy cohorts, thirty-three cohorts from The Cancer Genome Atlas (TCGA), and sixteen cohorts from the Gene Expression Omnibus (GEO), two of which involve single-cell transcriptomic data. Our findings indicate that aberrant USP11 expression is predictive of survival outcomes across various cancer types. The highest frequency of genomic alterations was observed in uterine corpus endometrial carcinoma (UCEC), with single-cell transcriptome analysis revealing significantly higher USP11 expression in plasmacytoid dendritic cells and mast cells. Notably, USP11 expression was associated with the infiltration levels of CD8+ T cells and natural killer (NK) activated cells. Additionally, in the skin cutaneous melanoma (SKCM) phs000452 cohort, patients with higher USP11 mRNA levels during immunotherapy experienced a significantly shorter median progression-free survival. USP11 emerges as a promising molecular biomarker with significant potential for predicting patient prognosis and immunoreactivity across various cancer types.
摘要:
USP11作为癌症的关键调节剂的重要性已经引起了广泛的关注,主要是由于其作为去泛素化酶的催化活性。尽管如此,在泛癌症研究中,USP11在各种癌症类型中的全面评估仍然缺乏.我们的分析整合了来自各种来源的数据,包括五个免疫疗法队列,来自癌症基因组图谱(TCGA)的33个队列,和来自基因表达综合(GEO)的16个队列,其中两个涉及单细胞转录组数据。我们的发现表明,异常的USP11表达可以预测各种癌症类型的生存结果。在子宫内膜癌(UCEC)中观察到最高的基因组改变频率,单细胞转录组分析显示,浆细胞样树突状细胞和肥大细胞中USP11表达明显更高。值得注意的是,USP11表达与CD8+T细胞和自然杀伤(NK)活化细胞的浸润水平相关。此外,在皮肤皮肤黑色素瘤(SKCM)phs000452队列中,在免疫治疗期间USP11mRNA水平较高的患者中位无进展生存期显著缩短.USP11作为一种有前途的分子生物标志物出现,具有预测患者预后和各种癌症类型的免疫反应性的巨大潜力。